APA (7th ed.) Citation

Kreckler L, Osinski M, Williams S, & Whiting R. (2022). Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis. Dove Medical Press.

Chicago Style (17th ed.) Citation

Kreckler L, Osinski M, Williams S, and Whiting R. Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis. Dove Medical Press, 2022.

MLA (9th ed.) Citation

Kreckler L, et al. Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis. Dove Medical Press, 2022.